Sitravatinib
- Generic Name
- Sitravatinib
- Drug Type
- Small Molecule
- Chemical Formula
- C33H29F2N5O4S
- CAS Number
- 1123837-84-2
- Unique Ingredient Identifier
- CWG62Q1VTB
- Background
Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 29
- Registration Number
- NCT02978859
- Locations
- 🇺🇸
Massachussetts General Hospital, Boston, Massachusetts, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT02954991
- Locations
- 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸USOR - Texas Oncology - Denison Cancer Center, Denison, Texas, United States
🇺🇸Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- Conditions
- AdenocarcinomaNon-Small Cell Lung CancerCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- 🇬🇧
Royal Devon and Exeter Hospital, Exeter, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT02219711
- Locations
- 🇺🇸
Guthrie Clinical Research, Sayre, Pennsylvania, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.